{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T17:18:11Z","timestamp":1760980691816},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.nucmedbio.2005.04.010","type":"journal-article","created":{"date-parts":[[2005,7,17]],"date-time":"2005-07-17T12:33:11Z","timestamp":1121603591000},"page":"613-622","source":"Crossref","is-referenced-by-count":18,"title":["Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET"],"prefix":"10.1016","volume":"32","author":[{"given":"Eskender","family":"Mume","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Orlova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per-Uno","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Lundqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sj\u00f6berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Tolmachev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2005.04.010_bib1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/028418699431410","article-title":"Positron emission tomography and radioimmunotargeting \u2014 general aspects","volume":"38","author":"Lundqvist","year":"1999","journal-title":"Acta Oncol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/bip.10348","article-title":"Targeting peptides and positron emission tomography","volume":"66","author":"Lundqvist","year":"2002","journal-title":"Biopolymers"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib3","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0969-8043(97)10129-4","article-title":"Production of 76Br by a low-energy cyclotron","volume":"49","author":"Tolmachev","year":"1998","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib4","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/02841860410028943","article-title":"A limiting factor for the progress of radionuclide based diagnostics and therapy; availability of suitable radionuclides","volume":"43","author":"Tolmachev","year":"2004","journal-title":"Acta Oncol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1118\/1.598512","article-title":"Kinetics of 76Br-labeled anti-CEA antibodies in pigs; aspects of dosimetry and PET imaging properties","volume":"26","author":"Lovqvist","year":"1999","journal-title":"Med Phys"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib6","unstructured":"Lubberink M. Quantitative imaging with PET: performance and applications of 76Br, 52Fe, 110mIn and 134 La. PhD Thesis, Uppsala University, Uppsala; 2001."},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0969-8051(94)E0065-Q","article-title":"76Br-Labeled monoclonal anti-CEA antibodies for radioimmuno positron emission tomography","volume":"22","author":"Lovqvist","year":"1995","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib8","first-page":"395","article-title":"Pharmacokinetics and experimental PET imaging of a bromine-76-labeled monoclonal anti-CEA antibody","volume":"38","author":"Lovqvist","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib9","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0969-8051(99)00076-1","article-title":"High-yield direct 76Br-bromination of monoclonal antibodies using the Chloramine-T","volume":"26","author":"Sundin","year":"1999","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0969-8051(00)00153-0","article-title":"Optimized indirect 76Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET","volume":"27","author":"H\u00f6glund","year":"2000","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib11","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.2174\/0929867033456666","article-title":"Approaches to improvement of cellular retention of radiohalogen labels delivered by internalizing tumor targeting proteins and peptides","volume":"10","author":"Tolmachev","year":"2003","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1096\/fasebj.7.5.8462781","article-title":"The design and application of residualizing labels for studies of protein catabolism","volume":"7","author":"Thorpe","year":"1993","journal-title":"FASEB J"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.nucmedbio.2003.08.005","article-title":"Radiobromination of monoclonal antibody using isothiocyanato derivative of closo-dodecaborate ([76Br]Bromo-DABI)","volume":"31","author":"Bruskin","year":"2004","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.nucmedbio.2003.11.007","article-title":"Radiobromination of anti-HER2\/neu\/erbB-2monoclonal antibody using the p-isothiocyanatobenzene derivative of the [76Br]undecahydro-bromo-7,8-dicarba-nido-undecaborate(1\u2212) ion","volume":"31","author":"Winberg","year":"2004","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/bc00007a009","article-title":"N-Succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates: a new class of reagents for protein radioiodination","volume":"2","author":"Garg","year":"1991","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0969-8051(93)90149-O","article-title":"Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate","volume":"20","author":"Garg","year":"1993","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib17","first-page":"4970","article-title":"Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate","volume":"56","author":"Reist","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib18","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0969-8051(97)00080-2","article-title":"In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent","volume":"24","author":"Reist","year":"1997","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib19","first-page":"1510","article-title":"Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate","volume":"57","author":"Reist","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0969-8051(98)00120-6","article-title":"Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate","volume":"26","author":"Reist","year":"1999","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0969-8051(98)00119-X","article-title":"Synthesis, purification, and in vitro stability of 211At- and 125I-labeled amidobisphosphonates","volume":"26","author":"Murud","year":"1999","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib22","first-page":"1539","article-title":"125I-Labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts","volume":"5","author":"Kuan","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib23","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0969-8051(99)00060-8","article-title":"Radioiodinated antibody targeting of the HER-2\/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution","volume":"26","author":"Zalutsky","year":"1999","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib24","first-page":"4453","article-title":"Radioiodination via d-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody","volume":"60","author":"Foulon","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0969-8051(00)00098-6","article-title":"Radioiodination and astatination of octreotide by conjugation labeling","volume":"27","author":"Vaidyanathan","year":"2000","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib26","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0969-8051(01)00239-6","article-title":"Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the d-amino acid peptide KRYRR","volume":"28","author":"Foulon","year":"2001","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1021\/bc0001490","article-title":"A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB)","volume":"12","author":"Vaidyanathan","year":"2001","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0969-8051(01)00277-3","article-title":"Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate","volume":"29","author":"Vaidyanathan","year":"2002","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0969-8051(03)00005-2","article-title":"N-Succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At","volume":"30","author":"Vaidyanathan","year":"2003","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ijc.2910450314","article-title":"Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues","volume":"45","author":"Natali","year":"1990","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib31","first-page":"953","article-title":"Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues","volume":"5","author":"Press","year":"1990","journal-title":"Oncogene"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/02841860260088836","article-title":"HER-2\u2014a possible target for therapy of metastatic urinary bladder carcinoma","volume":"41","author":"Wester","year":"2002","journal-title":"Acta Oncol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib33","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/sj.bjc.6601881","article-title":"HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review","volume":"90","author":"Carlsson","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib35","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1200\/JCO.1998.16.2.462","article-title":"Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers","volume":"16","author":"Sj\u00f6gren","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jemt.10181","article-title":"Prognostic and predictive value of HER2\/neu oncogene in breast cancer","volume":"59","author":"Masood","year":"2002","journal-title":"Microsc Res Tech"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/cncr.11476","article-title":"Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study","volume":"98","author":"Hogdall","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib38","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.1996.14.10.2702","article-title":"c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases","volume":"14","author":"Carlomagno","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib39","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1056\/NEJM199405053301802","article-title":"c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer","volume":"330","author":"Muss","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/cbr.1999.14.5","article-title":"Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer","volume":"14","author":"Dillman","year":"1999","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0149-2918(00)88288-0","article-title":"Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer","volume":"21","author":"Goldenberg","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib42","article-title":"Table of radioactive isotopes","author":"Browne","year":"1986"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib43","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0969-8051(00)00159-1","article-title":"Determination of specific radioactivity for 76Br-labeled compounds measuring the ratio between 76Br and 79Br using packed capillary liquid chromatography mass spectrometry","volume":"27","author":"Forngren","year":"2000","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib44","first-page":"1293","article-title":"Differences in experimental tumor localisation of dual-labeled monoclonal antibody","volume":"27","author":"Khaw","year":"1986","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib45","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1042\/bj2120791","article-title":"A radioiodinated, intracellularly trapped ligand for determining the sites of plasma protein degradation in vivo","volume":"212","author":"Pittman","year":"1983","journal-title":"Biochem J"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib46","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0003-9861(85)90071-2","article-title":"125I-Glycoconjugate labels for identifying sites of protein catabolism in vivo: effect of structure and chemistry of coupling to protein on label entrapment in cells after protein degradation","volume":"240","author":"Strobel","year":"1985","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib47","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0969-8051(88)80015-5","article-title":"Synthesis and radioiodination of tyramine cellobiose for labeling monoclonal antibodies","volume":"15","author":"Ali","year":"1988","journal-title":"Int J Radiat Appl Instrum B"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib48","first-page":"391","article-title":"Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human nonsmall-cell carcinoma of the lung","volume":"38","author":"Stein","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib49","first-page":"4375","article-title":"Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts","volume":"55","author":"Reist","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib50","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1021\/bc034003n","article-title":"Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate containing linker. Comparison with other radioiodination methods","volume":"14","author":"Nestor","year":"2003","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2005.04.010_bib51","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1007\/s00259-003-1308-9","article-title":"Combined effect of gefitinib (\u201cIressa\u201d, ZD1839) and targeted radiotherapy with 211At-EGF","volume":"30","author":"Sundberg","year":"2003","journal-title":"Eur J Nucl Med"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980510500106X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980510500106X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T21:30:26Z","timestamp":1551907826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096980510500106X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S096980510500106X"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2005.04.010","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}